Imad M Hariri1, Todd Dardas2, Manreet Kanwar3, Rebecca Cogswell4, Igor Gosev5, Ezequiel Molina6, Susan L Myers7, James K Kirklin7, Palak Shah8, Francis D Pagani9, Jennifer A Cowger10. 1. Henry Ford Hospitals, Detroit, Michigan. 2. University of Washington, Seattle, Washington. 3. Allegheny Health Network, Pittsburgh, Pennsylvania. 4. University of Minnesota, Minneapolis, Minnesota. 5. University of Rochester, Rochester, New York. 6. MedStar Heart & Vascular Institute/MedStar Washington Hospital Center, Washington, District of Columbia. 7. University of Alabama at Birmingham, Birmingham, Alabama. 8. Inova Heart & Vascular Institute, Falls Church, Virginia. 9. University of Michigan Cardiovascular Center, Ann Arbor, Michigan. 10. Henry Ford Hospitals, Detroit, Michigan. Electronic address: jennifercowger@gmail.com.
Abstract
BACKGROUND: Preoperative variables can predict short term left ventricular assist device (LVAD) survival, but predictors of extended survival remain insufficiently characterized. METHOD: Patients undergoing LVAD implant (2012-2018) in the Intermacs registry were grouped according to time on support: short-term (<1 year, n = 7,483), mid-term (MT, 1-3 years, n = 5,976) and long-term (LT, ≥3 years, n = 3,015). Landmarked hazard analyses (adjusted hazard ratio, HR) were performed to identify correlates of survival after 1 and 3 years of support. RESULTS: After surviving 1 year of support, additional LVAD survival was less likely in older (HR 1.15 per decade), Caucasian (HR 1.22) and unmarried (HR 1.16) patients (p < 0.05). After 3 years of support, only 3 preoperative characteristics (age, race, and history of bypass surgery, p < 0.05) correlated with extended survival. Postoperative events most negatively influenced achieving LT survival. In those alive at 1 year or 3 years, the occurrence of postoperative renal (creatinine HR MT = 1.09; LT HR = 1.10 per mg/dl) and hepatic dysfunction (AST HR MT = 1.29; LT HR = 1.34 per 100 IU), stroke (MT HR = 1.24; LT HR = 1.42), infection (MT HR = 1.13; LT HR = 1.10), and/or device malfunction (MT HR = 1.22; LT HR = 1.46) reduced extended survival (all p ≤ 0.03). CONCLUSIONS: Success with LVAD therapy hinges on achieving long term survival in more recipients. After 1 year, extended survival is heavily constrained by the occurrence of adverse events and postoperative end-organ dysfunction. The growth of destination therapy intent mandates that future LVAD studies be designed with follow up sufficient for capturing outcomes beyond 24 months.
BACKGROUND: Preoperative variables can predict short term left ventricular assist device (LVAD) survival, but predictors of extended survival remain insufficiently characterized. METHOD: Patients undergoing LVAD implant (2012-2018) in the Intermacs registry were grouped according to time on support: short-term (<1 year, n = 7,483), mid-term (MT, 1-3 years, n = 5,976) and long-term (LT, ≥3 years, n = 3,015). Landmarked hazard analyses (adjusted hazard ratio, HR) were performed to identify correlates of survival after 1 and 3 years of support. RESULTS: After surviving 1 year of support, additional LVAD survival was less likely in older (HR 1.15 per decade), Caucasian (HR 1.22) and unmarried (HR 1.16) patients (p < 0.05). After 3 years of support, only 3 preoperative characteristics (age, race, and history of bypass surgery, p < 0.05) correlated with extended survival. Postoperative events most negatively influenced achieving LT survival. In those alive at 1 year or 3 years, the occurrence of postoperative renal (creatinine HR MT = 1.09; LT HR = 1.10 per mg/dl) and hepatic dysfunction (AST HR MT = 1.29; LT HR = 1.34 per 100 IU), stroke (MT HR = 1.24; LT HR = 1.42), infection (MT HR = 1.13; LT HR = 1.10), and/or device malfunction (MT HR = 1.22; LT HR = 1.46) reduced extended survival (all p ≤ 0.03). CONCLUSIONS: Success with LVAD therapy hinges on achieving long term survival in more recipients. After 1 year, extended survival is heavily constrained by the occurrence of adverse events and postoperative end-organ dysfunction. The growth of destination therapy intent mandates that future LVAD studies be designed with follow up sufficient for capturing outcomes beyond 24 months.
Authors: Mandeep R Mehra; Nir Uriel; Yoshifumi Naka; Joseph C Cleveland; Melana Yuzefpolskaya; Christopher T Salerno; Mary N Walsh; Carmelo A Milano; Chetan B Patel; Steven W Hutchins; John Ransom; Gregory A Ewald; Akinobu Itoh; Nirav Y Raval; Scott C Silvestry; Rebecca Cogswell; Ranjit John; Arvind Bhimaraj; Brian A Bruckner; Brian D Lowes; John Y Um; Valluvan Jeevanandam; Gabriel Sayer; Abeel A Mangi; Ezequiel J Molina; Farooq Sheikh; Keith Aaronson; Francis D Pagani; William G Cotts; Antone J Tatooles; Ashok Babu; Don Chomsky; Jason N Katz; Paul B Tessmann; David Dean; Arun Krishnamoorthy; Joyce Chuang; Ia Topuria; Poornima Sood; Daniel J Goldstein Journal: N Engl J Med Date: 2019-03-17 Impact factor: 91.245
Authors: Manreet K Kanwar; Lisa C Lohmueller; Robert L Kormos; Jeffrey J Teuteberg; Joseph G Rogers; JoAnn Lindenfeld; Stephen H Bailey; Colleen K McIlvennan; Raymond Benza; Srinivas Murali; James Antaki Journal: JACC Heart Fail Date: 2018-08-08 Impact factor: 12.035
Authors: Jennifer A Cowger; Matthew A Romano; Palak Shah; Neha Shah; Vivek Mehta; Jonathan W Haft; Keith D Aaronson; Francis D Pagani Journal: J Heart Lung Transplant Date: 2013-11-28 Impact factor: 10.247
Authors: Paolo C Colombo; Mandeep R Mehra; Daniel J Goldstein; Jerry D Estep; Christopher Salerno; Ulrich P Jorde; Jennifer A Cowger; Joseph C Cleveland; Nir Uriel; Gabriel Sayer; Eric R Skipper; Francis X Downey; Masahiro Ono; Robert Hooker; Anelechi C Anyanwu; Michael M Givertz; Claudius Mahr; Ia Topuria; Sami I Somo; Daniel L Crandall; Douglas A Horstmanshof Journal: Circulation Date: 2019-01-08 Impact factor: 29.690
Authors: James K Kirklin; Francis D Pagani; Robert L Kormos; Lynne W Stevenson; Elizabeth D Blume; Susan L Myers; Marissa A Miller; J Timothy Baldwin; James B Young; David C Naftel Journal: J Heart Lung Transplant Date: 2017-07-15 Impact factor: 10.247
Authors: Carmelo A Milano; Joseph G Rogers; Antone J Tatooles; Geetha Bhat; Mark S Slaughter; Emma J Birks; Nahush A Mokadam; Claudius Mahr; Jeffrey S Miller; David W Markham; Valluvan Jeevanandam; Nir Uriel; Keith D Aaronson; Thomas A Vassiliades; Francis D Pagani Journal: JACC Heart Fail Date: 2018-07-11 Impact factor: 12.035
Authors: Jeffrey J Teuteberg; Joseph C Cleveland; Jennifer Cowger; Robert S Higgins; Daniel J Goldstein; Mary Keebler; James K Kirklin; Susan L Myers; Christopher T Salerno; Josef Stehlik; Felix Fernandez; Vinay Badhwar; Francis D Pagani; Pavan Atluri Journal: Ann Thorac Surg Date: 2020-03 Impact factor: 4.330
Authors: Jennifer Cowger; Kartik Sundareswaran; Joseph G Rogers; Soon J Park; Francis D Pagani; Geetha Bhat; Brian Jaski; David J Farrar; Mark S Slaughter Journal: J Am Coll Cardiol Date: 2012-12-19 Impact factor: 24.094
Authors: James K Kirklin; David C Naftel; Susan L Myers; Francis D Pagani; Paolo C Colombo Journal: J Heart Lung Transplant Date: 2020-04-21 Impact factor: 10.247
Authors: Ezequiel J Molina; Palak Shah; Michael S Kiernan; William K Cornwell; Hannah Copeland; Koji Takeda; Felix G Fernandez; Vinay Badhwar; Robert H Habib; Jeffrey P Jacobs; Devin Koehl; James K Kirklin; Francis D Pagani; Jennifer A Cowger Journal: Ann Thorac Surg Date: 2021-01-16 Impact factor: 4.330
Authors: Michael J Pienta; Xiaoting Wu; Thomas M Cascino; Alexander A Brescia; Ashraf Abou El Ela; Min Zhang; Jeffrey S McCullough; Supriya Shore; Keith D Aaronson; Michael P Thompson; Francis D Pagani; Donald S Likosky Journal: Ann Thorac Surg Date: 2022-02-15 Impact factor: 5.102